摘要
目的探讨冠脉介入术(PCI)术前应用瑞舒伐他汀对非ST段抬高型急性冠脉综合征患者血浆和肽素(CPP)、血浆水溶性凝集素样氧化低密度脂蛋白受体-1(s LOX-1)和左心室射血分数(LVEF)的影响。方法选取非ST段抬高型急性冠脉综合征患者150例,对照组和观察组各75例。对照组PCI术前口服阿托伐汀,观察组口服瑞舒伐他汀。检测PCI术前和术后7 d患者血浆CPP、s LOX-1水平,观察LVEF、左心室舒张末期内径(LVEDD);统计术后30 d患者主要不良心血管事件(MACE)的发生。结果PCI术后7天两组患者血浆CPP、s LOX-1水平较术前均明显下降,差异有统计学意义(P<0.05),其中观察组降低更明显(P<0.05)。术后7天两组患者LVEF较术前均明显升高,差异有统计学意义(P<0.05),其中观察组升高更明显(P<0.05);两组患者LVEDD较术前有所降低,但无统计学意义(P>0.05)。术后30天观察组发生MACE明显低于对照组,差异有统计学意义(P<0.05)。结论PCI术前应用瑞舒伐他汀可显著降低非ST段抬高型急性冠脉综合征患者血浆CPP和s LOX-1水平,改善心功能,降低MACE的发生。
Objective To investigate the effects of oral rosuvastatin before percutaneous coronary intervention(PCI)on plasma levels of copeptin(CPP),soluble lectin-like oxidized low-density lipoprotein receptor-1(s LOX-1)and left ventricular ejection fraction(LVEF)in patients with non-ST segment elevation acute coronary syndromes(NSTE-ACS).Methods 150 patients with NSTE-ACS,75 patients in control group and 75 patients in observation group were selected.Before PCI the control group was treated with atorvatatin and the observation group with rosuvastatin respectively.The plasma levels of CPP,s LOX-1 were detected on preoperative and postoperative 7 days.LVEF and left ventricular end-diastolic diameter(LVEDD)were observed by echocardiography at the same time.The incidence of main adverse cardiovascular events(MACE)were recorded during postoperative30 days.Results The levels of plasma CPP and s LOX-1 in both groups were significantly decreased after PCI(P<0.05);In the observation group,the decrease was more obviously(P<0.05).LVEF was increased in both groups after PCI(P<0.05),and LVEF in the observation group wasincreased more obviously(P<0.05).The incidence of MACE in the observation group was significantly lower than that in the control group(P<0.05)during postoperative30 days.Conclusion Preoperative application of rosuvastatin can significantly reduce plasma CPP and s LOX-1 levels,improve cardiac function and decrease the occurrence of MACE in patients with NSTE-ACS.
作者
郑珂
ZHENG Ke(Department of Cardiology,The Liaoning University of Traditional Chinese Medicine Affiliated to the Fourth Hospital,Shenyang,110101,China)
出处
《血栓与止血学》
2020年第3期377-380,共4页
Chinese Journal of Thrombosis and Hemostasis
关键词
急性冠脉综合征
冠状动脉介入术
瑞舒伐他汀
临床疗效
Acute coronary syndrome
Percutaneous coronary intervention
Rosuvastatin
Clinical efficacy
